MedTrace Logo

Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer

NCT06954233 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-07-16

No results posted yet for this study

Summary

This study aims to evaluate how retroperitoneal lymph node dissection (RPLND), a surgical treatment for testicular cancer, may affect urinary and sexual functions in men. RPLND involves the removal of lymph nodes from the abdominal area and is sometimes necessary in patients who are not eligible for chemotherapy or who have residual disease after chemotherapy. While this surgery is known to carry a risk of affecting ejaculation, its potential impact on other areas such as urination or erection is not well understood.

The study will prospectively follow adult men undergoing RPLND. It will assess changes in lower urinary tract symptoms, urine flow, ejaculation, erection, and overall quality of life before surgery and during follow-up visits up to 6 months after the operation. Patients will complete standardized questionnaires and undergo simple, non-invasive tests such as urine flow measurement.

By identifying how RPLND may influence urinary and sexual health, this study seeks to improve understanding of the full range of effects of this treatment. The findings may help clinicians better inform patients before surgery and support improved post-operative care.

Conditions

  • Testicular Cancer

Interventions

DIAGNOSTIC_TEST

Uroflowmetry and questionnaires

Uroflowmetry - urine flow assessment Questionnaires: IPSS, ICIQ-MLUTS, IIEF-5, MSHQ-EjD, EQ-5D-5L

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Anna K. Czech, M.D. · Jagiellonian University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-14
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06954233 on ClinicalTrials.gov